MBI begins clinical trials of FS069

March 15, 1995

Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of

Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of Albunex, the firstultrasound contrast agent approved for marketing in the U.S (SCAN8/31/94).